Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Histone deacetylases (HDACs) have been proved to be promising targets for the treatment of cancer, and five histone deacetylase inhibitors (HDACis) have been approved on the market for the treatment of different lymphomas. In our previous work, we designed a series of novel coumarin-containing hydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Na, Yang, Feifei, Han, Lina, Qu, Yuhua, Ge, Di, Zhang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036849/
https://www.ncbi.nlm.nih.gov/pubmed/32046013
http://dx.doi.org/10.3390/molecules25030717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036849/
https://www.ncbi.nlm.nih.gov/pubmed/32046013
http://dx.doi.org/10.3390/molecules25030717

Ejemplares similares